Publications by authors named "Quentin M Anstee"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

32,264

Total Likes

2,202

Extended Reach

2,431,714

Social Features

358
A
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E Moussa, Guy W Neff, Mary E Rinella

N Engl J Med· February 2024

Videos about Article: user user user 5

8 2 4 222 10 86

View All Article and Social Media Activity
A
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.
Mohammed Eslam, Philip N Newsome, Shiv K Sarin, Quentin M Anstee, Giovanni Targher, Manuel Romero-Gomez, Shira Zelber-Sagi, Vincent Wai-Sun Wong, Jean-François Dufour, Jörn M Schattenberg

J Hepatol· July 2020

Videos about Article: user user

2 3 124 3 21

View All Article and Social Media Activity
I
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related Mortality.
Carolin V Schneider, Stefan Gross, Sriram Balasubramani, Petra Tomanová, Christina Schrader, Quentin M Anstee

Clin Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Luis Antonio Diaz, Maja Thiele, Alexandre Louvet, Brian P Lee, Veeral Ajmera, Quentin M Anstee

Nat Rev Gastroenterol Hepatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food Insecurity Is Highly Prevalent Amongst Patients With Chronic Liver Disease in Northern England: A Cross-Sectional Analysis.
Rachel Howarth, Thomas Crame, Stuart McPherson, Quentin M Anstee, Laura Haigh

J Hum Nutr Diet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world work productivity is impaired in people with metabolic dysfunction-associated steatotic liver disease in the USA.
Shraddha Shinde, Mary E Rinella, Mark L Hartman, David Schapiro, Victoria Higgins, Quentin M Anstee

JHEP Rep· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2-F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study.
Vincent Wai-Sun Wong, Neeta B Amin, Hirokazu Takahashi, Amanda Darekar, Frank Tacke, Quentin M Anstee

Lancet Gastroenterol Hepatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis.
Maximilian Jara, Jenny Norlin, Mette Skalshøi Kjær, Kasper Almholt, Kristian M Bendtsen, Quentin M Anstee

Nat Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH.
Louise Maymann Nitze, Vlad Ratziu, Arun J Sanyal, Vincent Wai-Sun Wong, Clare Balendran, Quentin M Anstee

Aliment Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Variants Influence Chronic Liver Disease Progression through Distinct Pathways.
Marijana Vujkovic, David E Kaplan, Jonas Ghouse, Bao-Li Loza, Joseph Brancale, Quentin M Anstee

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.
Andressa de Zawadzki, Diana J Leeming, Arun J Sanyal, Quentin M Anstee, Jörn M Schattenberg

J Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NASH-CHECK patient-reported outcome instrument: evaluation of content and face validity for patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.
Lynda C Doward, Matthew Breckons, Maria-Magdalena Balp, James Twiss, Luke Vale, Quentin M Anstee

J Patient Rep Outcomes· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ECM formation and degradation during fibrosis, repair, and regeneration.
Alejandro E Mayorca-Guiliani, Diana Julie Leeming, Kim Henriksen, Joachim Høg Mortensen, Signe Holm Nielsen, Quentin M Anstee

NPJ Metab Health Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.
Zobair M Younossi, Homie Razavi, Michael Sherman, Alina M Allen, Quentin M Anstee

Aliment Pharmacol Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to: Precision in Diagnosis of Liver Fibrosis in MASLD: Machine Learning Based Scores May Be More Accurate Than Conventional NITs.
Yasaman Vali, Quentin M Anstee, Patrick M Bossuyt

Liver Int· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States.
Mary E Rinella, Mark L Hartman, Shraddha Shinde, David Schapiro, Victoria Higgins, Quentin M Anstee

Clin Gastroenterol Hepatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision in Liver Diagnosis: Varied Accuracy Across Subgroups and the Need for Variable Thresholds in Diagnosis of MASLD.
Yasaman Vali, Anne-Marieke van Dijk, Jenny Lee, Jerome Boursier, Vlad Ratziu, Quentin M Anstee

Liver Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Mazen Noureddin, Emily Truong, Rebeca Mayo, Ibon Martínez-Arranz, Itziar Mincholé, Quentin M Anstee

Hepatology· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical validation of an AI-based pathology tool for scoring of metabolic dysfunction-associated steatohepatitis.
Hanna Pulaski, Stephen A Harrison, Shraddha S Mehta, Arun J Sanyal, Marlena C Vitali, Quentin M Anstee

Nat Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A roadmap for clinical trials in MASH-related compensated cirrhosis.
Juan M Pericàs, Quentin M Anstee, Salvador Augustin, Ramón Bataller, Annalisa Berzigotti

Nat Rev Gastroenterol Hepatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: A roadmap for clinical trials in MASH-related compensated cirrhosis.
Juan M Pericàs, Quentin M Anstee, Salvador Augustin, Ramón Bataller, Annalisa Berzigotti

Nat Rev Gastroenterol Hepatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis.
Silvia Sabatini, Partho Sen, Fabrizia Carli, Samantha Pezzica, Chiara Rosso, Quentin M Anstee

Cell Rep Med· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply.
Stuart McPherson, Jessica K Dyson, Laura Jopson, Steven Masson, Preya Patel, Quentin M Anstee

Aliment Pharmacol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter: Beyond advanced fibrosis-The critical need for assessing NITs performance in identifying F2-F3 fibrosis. Authors' reply.
Stuart McPherson, Jessica K Dyson, Laura Jopson, Steven Masson, Preya Patel, Quentin M Anstee

Aliment Pharmacol Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease?
Stuart McPherson, Jessica K Dyson, Laura Jopson, Steven Masson, Preya Patel, Quentin M Anstee

Aliment Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis.
Elena Sena, Frank Tacke, Quentin M Anstee, Nicholas Di Prospero, Mette Skalshøi-Kjær

Commun Med (Lond)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder, Fiona Oakley, Christian Trautwein, Quentin M Anstee

Nat Metab· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis